Deals
Onyx Shares Climb on Optimism of Possible Sale of Company
This article is for subscribers only.
Onyx Pharmaceuticals Inc., the developer of the kidney-cancer treatment Nexavar, climbed 4.4 percent in New York trading on optimism the company may be sold.
Onyx rose $1.88 to $44.68 at the close. The shares of the South San Francisco, California-based drug developer surged 14 percent yesterday after two people with knowledge of the matter said the company is exploring options including a possible sale.